JNJ•benzinga•
Johnson & Johnson Announces Initial Phase 1 Results Of JNJ-79635322, Investigational TsAb In Patients With Relapsed Or Refractory Multiple Myeloma
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on June 3, 2025 by benzinga